A comparative study of the effects of oral magnesium versus placebo in migraine prophylaxis in pregnancy period

Comparison of oral magnesium and placebo in migraine prophylaxis in pregnancy period

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016062128559N1

Enrollment

Registered

2016-11-14

Start date

2015-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Common Migraine. Condition 2: Classical Migraine. Migraine without aura (common migraine) Migraine with aura (classical migraine)

Interventions

Intervention 1: Magnesium Oxide, 250 mg tablets, 2 times a day (Minoo Company), for 12 weeks. Intervention 2: Placebo tablets identical to magnesium tablets in shape and color, 2 times a day, for 12 w

Treatment - Drugs

Placebo

Magnesium Oxide, 250 mg tablets, 2 times a day (Minoo Company), for 12 weeks

Placebo tablets identical to magnesium tablets in shape and color, 2 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of Kermanshah University of Medical Sciences.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis of migraine according to definition of International Headache Society by a neurologist; at least one year has passed form the time of migraine onset; moderate to severe headache; more than 2 headache attacks per month. Exclusion criteria: Having tension headaches or other non-migraine headaches; overuse of analgesic medications (more than 15 days a month); use of any migraine prophylactic drugs; history of previous or recently infection; history of chronic diseases (diabetes, hypertension, cardiac, vascular, renal and hepatic); use of mineral supplements; substance and alcohol abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of headache. Timepoint: In each migraine attack. Method of measurement: Patient will record the headache severity in daily notes as VAS, MIDAS,HITS-6& physician registers them every 4 weeks.;Duration of migraine attack. Timepoint: In each migraine attack. Method of measurement: Patient records the hours of headache in each attack , physician registers them every 4 weeks.;Headache frequency. Timepoint: In each migraine attack. Method of measurement: According to patient records.;Analgesic use. Timepoint: Every 4 week. Method of measurement: According to patient records.	—

Measure

Time frame

Severity of headache. Timepoint: In each migraine attack. Method of measurement: Patient will record the headache severity in daily notes as VAS, MIDAS,HITS-6& physician registers them every 4 weeks.;Duration of migraine attack. Timepoint: In each migraine attack. Method of measurement: Patient records the hours of headache in each attack , physician registers them every 4 weeks.;Headache frequency. Timepoint: In each migraine attack. Method of measurement: According to patient records.;Analgesic use. Timepoint: Every 4 week. Method of measurement: According to patient records.

—

Secondary

Measure	Time frame
Clinical side effects. Timepoint: Every 4 weeks. Method of measurement: According to patients notes.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Moradian

Kermanshah University of Medical Sciences

na_moradian@kums.ac.ir; moradiannasrin60@yahoo.com+98 83 3836 2562

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026